Spots Global Cancer Trial Database for iodine i 131 tositumomab
Every month we try and update this database with for iodine i 131 tositumomab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab | NCT00240578 | Lymphoma, Non-H... | 18 Years - | GlaxoSmithKline | ||
| Expanded Access Study of Iodine-131 Anti-B1 Antibody | NCT00022958 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma | NCT00315731 | Lymphoma, Folli... | Follicular Lymp... | 18 Years - | GlaxoSmithKline | |
| Expanded Access Study of Iodine-131 Anti-B1 Antibody | NCT00022958 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00110071 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac... | fludarabine pho... peripheral bloo... iodine I 131 to... laboratory biom... flow cytometry polymerase chai... | 60 Years - | Fred Hutchinson Cancer Center | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia | NCT00022880 | Chronic Lymphoc... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00110071 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac... | fludarabine pho... peripheral bloo... iodine I 131 to... laboratory biom... flow cytometry polymerase chai... | 60 Years - | Fred Hutchinson Cancer Center | |
| Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00073918 | Anaplastic Larg... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac... | cyclophosphamid... etoposide iodine I 131 to... quality-of-life... peripheral bloo... | 18 Years - 60 Years | Fred Hutchinson Cancer Center | |
| Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies | NCT01224821 | Lymphoma, Non-H... | Tositumomab (An... | 18 Years - | GlaxoSmithKline | |
| Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab | NCT00240591 | Lymphoma, Non-H... | 18 Years - | GlaxoSmithKline | ||
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP | NCT00022932 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - 80 Years | Corixa Corporation | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma | NCT00022893 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab | NCT00240591 | Lymphoma, Non-H... | 18 Years - | GlaxoSmithKline | ||
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | NCT00022945 | Mantle Cell Lym... | Iodine-131 Anti... Cyclophosphamid... | 18 Years - | Corixa Corporation | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement | NCT00022906 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement | NCT00022906 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | NCT00319332 | Lymphoma, Small... Lymphoma, Large... Lymphoma, Folli... Lymphoma, Non-H... | Ibritumomab Tiu... Iodine I 131 To... | 18 Years - | GlaxoSmithKline | |
| Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma | NCT00135200 | Multiple Myelom... | Iodine I 131 To... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma | NCT00022893 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab | NCT00062894 | Non-Hodgkin's L... | Iodine I 131 To... | 18 Years - | GlaxoSmithKline | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia | NCT00022880 | Chronic Lymphoc... | Iodine-131 Anti... | 18 Years - | Corixa Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
